Breaking: Leerink Partners Reaffirms $196.0000 PT On Sarepta Therapeutics (NASDAQ:SRPT) Shares, Reaffirms Their Original “Buy” Rating

June 21, 2018 - By Mona Holcomb

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo

Investors sentiment decreased to 0.97 in 2018 Q1. Its down 0.25, from 1.22 in 2017Q4. It dived, as 31 investors sold Sarepta Therapeutics, Inc. shares while 81 reduced holdings. 45 funds opened positions while 64 raised stakes. 54.74 million shares or 3.52% more from 52.88 million shares in 2017Q4 were reported.

Stifel Fin invested in 33,436 shares or 0.01% of the stock. Crow Point Prtn Ltd Liability has 0.01% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Hall Laurie J Trustee reported 0% stake. Eagle Asset Mgmt owns 0.39% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 979,541 shares. Adage Cap Prns Ltd invested in 100,000 shares. C Worldwide A S reported 0.08% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Granite Point Capital L P holds 0.22% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 31,020 shares. Aqr Capital Limited Liability Corporation stated it has 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Stratos Wealth Prns Ltd owns 500 shares. Amundi Pioneer Asset Mngmt invested in 49,662 shares. Axa stated it has 59,593 shares. Jpmorgan Chase And has 0.01% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 709,070 shares. 63,009 are held by American Century Companies. Bnp Paribas Arbitrage reported 17,582 shares. Atlantic Trust Gru Llc accumulated 0% or 9,280 shares.

Sarepta Therapeutics (NASDAQ:SRPT) Rating Reaffirmed

In analysts report published this morning, Leerink Partners kept their “Buy” rating on Sarepta Therapeutics (NASDAQ:SRPT) shares. The target price would suggest a possible upside of 30.54 % from company’s close price.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 18 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 16 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. Sarepta Therapeutics has $267 highest and $55.0 lowest target. $129.13’s average target is -14.00% below currents $150.1475 stock price. Sarepta Therapeutics had 33 analyst reports since January 3, 2018 according to SRatingsIntel. SunTrust maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Wednesday, March 7 with “Buy” rating. The firm earned “Buy” rating on Monday, March 12 by Piper Jaffray. As per Thursday, May 3, the company rating was downgraded by Oppenheimer. Morgan Stanley maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Friday, May 4. Morgan Stanley has “Equal-Weight” rating and $91 target. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Buy” rating by Leerink Swann on Friday, January 19. SunTrust maintained the shares of SRPT in report on Thursday, March 15 with “Buy” rating. Cowen & Co maintained the stock with “Buy” rating in Wednesday, June 20 report. As per Friday, February 9, the company rating was maintained by Piper Jaffray. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Outperform” rating given on Friday, May 4 by Credit Suisse. The stock has “Equal-Weight” rating by Morgan Stanley on Wednesday, June 20.

The stock decreased 2.30% or $3.5425 during the last trading session, reaching $150.1475. About 1.44M shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 197.08% since June 21, 2017 and is uptrending. It has outperformed by 184.51% the S&P500.

Analysts await Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report earnings on July, 18. They expect $-0.57 EPS, up 50.43 % or $0.58 from last year’s $-1.15 per share. After $-0.44 actual EPS reported by Sarepta Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 29.55 % negative EPS growth.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $9.84 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Seekingalpha.com which released: “EMA’s advisory committee thumbs down on Sarepta’s Exondys” on June 01, 2018, also Globenewswire.com with their article: “Recent Analysis Shows First Interstate BancSystem, Spectrum Brands, Sarepta Therapeutics, Capstone Turbine, Main …” published on June 20, 2018, Benzinga.com published: “10 Biggest Price Target Changes For Thursday” on June 21, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Seekingalpha.com and their article: “Gene Therapy For Duchenne” published on June 20, 2018 as well as Marketwatch.com‘s news article titled: “Nasdaq notches record; Dow extends losing streak to 7 days” with publication date: June 20, 2018.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: